美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

UTHR 美国联合医疗

盘前交易 08-24 06:59:33 EDT

513.12

-7.88

-1.51%

最高528.02	最低512.29	成交量41.56万
今开523.23	昨收521.00	日振幅3.02%
总市值220.08亿	流通市值201.91亿	总股本4,289万
成交额2.15亿	换手率1.06%	流通股本3,935万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"UTHR","market":"US","secType":"STK","nameCN":"美国联合医疗","latestPrice":513.12,"timestamp":1787342400000,"preClose":521,"halted":0,"volume":415573,"delay":0,"changeRate":-0.015124760076775424,"floatShares":39350000,"shares":42890700,"eps":27.94838,"marketStatus":"盘前交易","change":-7.88,"latestTime":"08-24 06:59:33 EDT","open":523.23,"high":528.02,"low":512.29,"amount":215184281.20219997,"amplitude":0.030192,"askPrice":528.99,"askSize":27,"bidPrice":325.42,"bidSize":40,"shortable":3,"etf":0,"ttmEps":27.94838,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":929592000000,"exchange":"NASDAQ","adjPreClose":513.12,"postHourTrading":{"tag":"盘后","latestPrice":513.31,"preClose":513.12,"latestTime":"19:30 EDT","volume":23328,"amount":11970253.74,"timestamp":1787355004044,"change":0.19,"changeRate":0.00037,"amplitude":0.00037},"volumeRatio":0.9578840175987251,"impliedVol":0.3443,"impliedVolPercentile":0.204},"requestUrl":"/m/hq/s/UTHR","defaultTab":"news","newsList":[{"id":"1196098833","title":"美国联合医疗宣布Teton-PPF研究完成入组：吸入性曲前列尼尔治疗进行性肺纤维化","url":"https://stock-news.laohu8.com/highlight/detail?id=1196098833","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196098833?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:01","pubTimestamp":1786964487,"startTime":"0","endTime":"0","summary":"美国联合医疗今日正式宣布，其针对吸入性曲前列尼尔治疗进行性肺纤维化的Teton-PPF研究已圆满完成全部患者入组。据悉，Teton-PPF研究是一项关键性临床试验，旨在评估吸入性曲前列尼尔在延缓进行性肺纤维化疾病进展方面的疗效与安全性。美国联合医疗表示，将继续致力于推进该项目的开发，以期早日为患者带来突破性疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","BK4139","LU1571399168.USD","BK4532","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167235408","title":"财报前瞻｜美国联合医疗本季度营收预计小幅增长，机构偏向审慎乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1167235408","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167235408?lang=zh_cn&edition=full","pubTime":"2026-07-30 00:09","pubTimestamp":1785341342,"startTime":"0","endTime":"0","summary":"美国联合医疗将在2026年08月05日发布最新季度财报，市场关注营收恢复与利润率稳定性以及核心吸入/雾化产品放量节奏。市场一致预期显示，本季度美国联合医疗营收预计为8.06亿美元，同比增长0.17%；EBIT预计为3.89亿美元，同比增长5.39%；预计调整后每股收益为6.83美元，同比下降1.56%。一线机构普遍认为，本季度收入有望回到小幅正增长轨道，EBIT率在费用投放平衡后趋于稳定，EPS虽受阶段性投入拖累但具备中期修复条件。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜美国联合医疗本季度营收预计小幅增长，机构偏向审慎乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169631569","title":"美国联合医疗：Ralinepag治疗肺动脉高压III期临床研究达到主要及次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1169631569","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169631569?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:34","pubTimestamp":1785321261,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其用于治疗肺动脉高压（PAH）的药物Ralinepag，在名为Advance Outcomes的III期临床研究中，成功达到了预设的主要终点与次要终点。这一突破性进展，为肺动脉高压患者带来了新的治疗希望。该研究结果不仅验证了药物的核心疗效，更在多个关键评估指标上展现出显著性优势，标志着Ralinepag在攻克这一罕见且凶险的疾病上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","BK4139","LU1571399168.USD","BK4532","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114839620","title":"美国联合医疗宣布Lungfx™设备获FDA批准用于集中式离体肺灌注","url":"https://stock-news.laohu8.com/highlight/detail?id=1114839620","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114839620?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:38","pubTimestamp":1782729494,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其Lungfx™设备已获得美国食品药品监督管理局的批准，可用于集中式的离体肺灌注操作。这一监管里程碑标志着公司在器官护理技术领域取得了重要进展，有望提升供体肺的评估、修复和利用效率，从而为更多等待肺移植的患者带来希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1699723380.USD","BK4139","LU1571399168.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185929543","title":"Varda Space Industries与联合医疗携手推进微重力罕见肺病疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185929543","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185929543?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:02","pubTimestamp":1778666549,"startTime":"0","endTime":"0","summary":"Varda Space Industries与联合医疗（United Therapeutics）达成合作，共同致力于利用微重力环境开发针对罕见肺部疾病的创新疗法。此次合作旨在探索太空环境对药物研发与生产可能带来的革命性影响，为相关治疗领域开辟新的技术路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1699723380.USD","UTHR","LU1571399168.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106467182","title":"美国联合医疗董事雷蒙德·德韦克教授荣休 曾获C.B.E.及F.R.S.殊荣","url":"https://stock-news.laohu8.com/highlight/detail?id=1106467182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106467182?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:08","pubTimestamp":1777460917,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics Corporation）近日宣布，公司董事会成员雷蒙德·德韦克教授（Professor Raymond Dwek, C.B.E., F.R.S.）正式退休。德韦克教授在任期间以其深厚的学术造诣和卓越贡献备受赞誉，其荣休标志着公司治理层一个重要时代的落幕。\n作为曾获授大英帝国司令勋章（C.B.E.）及英国皇家学会院士（F.R.S.）的杰出科学家，德韦克教授在生物医学领域的专业见解为董事会决策提供了重要支撑。他的离任虽令人不舍，但公司对其多年来的服务表示深切感谢，并祝愿他在未来的学术与生活中再创辉煌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","LU1699723380.USD","LU1571399168.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180302098","title":"美国联合医疗：Raymond James首予跑赢大市评级，目标价700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180302098","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180302098?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:24","pubTimestamp":1775820297,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）近日获得Raymond James的首次覆盖，该机构给予其\"跑赢大市\"评级，并将目标股价设定为700美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4532","BK4139","LU1699723380.USD","UTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159418166","title":"美国联合医疗Miroliverelap®获FDA再生医学先进疗法认定，用于急性肝衰竭治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1159418166","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159418166?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:03","pubTimestamp":1775646225,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其研发的药物Miroliverelap®已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定，适应症为急性肝衰竭。这一认定将加速该疗法的开发和审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1699723380.USD","UTHR","LU1571399168.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161460841","title":"美国联合医疗股价飙升14.71%：吸入式药物Tyvaso在晚期特发性肺纤维化研究中达成主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1161460841","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161460841?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:32","pubTimestamp":1774877577,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其吸入式药物Tyvaso在一项针对特发性肺纤维化的晚期临床研究中成功达成主要试验目标。受此利好消息提振，该公司股价大幅跃升14.71%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4139","BK4532","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109130837","title":"美国联合医疗计划为Tyvaso申请优先审评 补充新药申请将于今夏末提交FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1109130837","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109130837?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:10","pubTimestamp":1774869014,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，将为旗下药物Tyvaso的补充新药申请（sNDA）寻求优先审评资格。该公司计划于今年夏季结束前向美国食品药品监督管理局（FDA）正式提交该项申请。\n优先审评资格将加速FDA对Tyvaso申请的审批流程，若获批准，有望使该药物更早惠及患者。此次申报标志着公司在拓展Tyvaso适应症方面迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","UTHR","BK4139","LU1571399168.USD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166965135","title":"美国联合医疗宣布Tyvaso®治疗特发性肺纤维化Teton-1关键研究达主要终点，疗效超越Teton-2显著成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1166965135","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166965135?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:03","pubTimestamp":1774868588,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布，其研发的Tyvaso®在治疗特发性肺纤维化的Teton-1关键性研究中成功达到主要临床终点。该研究展现的治疗效果甚至超越了此前Teton-2研究中已令人瞩目的数据，标志着其在IPF治疗领域取得重大突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","UTHR","BK4139","LU1571399168.USD","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177276682","title":"美国联合医疗TETON-2研究达主要终点 Tyvaso治疗52周显著改善患者绝对FVC","url":"https://stock-news.laohu8.com/highlight/detail?id=1177276682","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177276682?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267316,"startTime":"0","endTime":"0","summary":"美国联合医疗宣布，其针对间质性肺病患者开展的TETON-2三期临床研究已达到主要终点。数据显示，治疗52周后，使用Tyvaso吸入溶液的患者在绝对用力肺活量指标上表现出具有统计学意义的显著改善。这项随机双盲安慰剂对照研究，旨在评估Tyvaso在改善ILD患者肺功能方面的疗效与安全性。公司表示将基于该研究结果与全球监管机构进行沟通，推动Tyvaso在更多地区的临床应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","UTHR","LU1699723380.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188280173","title":"美国联合医疗Tyvaso耐受性良好 安全性特征与既往研究一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1188280173","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188280173?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267315,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布的最新数据显示，其肺动脉高压治疗药物Tyvaso表现出良好的耐受性，药物安全性特征与先前临床试验结果保持一致。\n研究结果显示，Tyvaso在长期使用过程中维持了稳定的安全特性，未出现新的安全性信号。该药物在改善患者运动耐量方面的疗效与已知数据相符，为肺动脉高压患者提供了持续有效的治疗选择。\n此次数据进一步巩固了Tyvaso在肺动脉高压治疗领域的地位，其一致的安全性特征为临床医生和患者提供了更可靠的用药依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","BK4139","LU1699723380.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128744146","title":"美国联合医疗公布Teton-2三期临床试验完整结果 发表于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1128744146","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128744146?lang=zh_cn&edition=full","pubTime":"2026-03-12 06:15","pubTimestamp":1773267313,"startTime":"0","endTime":"0","summary":"美国联合医疗公司（United Therapeutics）宣布，其Teton-2三期临床试验的完整研究结果已在权威医学期刊《新英格兰医学杂志》上正式发表。该试验的全面数据披露，标志着公司在相关治疗领域的研究取得了重要阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UTHR","BK4532","LU1699723380.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618676824","title":"美国联合医疗涨4.57% 股价突破500美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2618676824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618676824?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:30","pubTimestamp":1773063025,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时30分，美国联合医疗股票出现波动，股价大幅上涨4.57%。截至发稿，该股报500.00美元/股，成交量1.0408万股，换手率0.02%，振幅0.94%。美国联合医疗股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Hims & Hers Health, Inc.、美国联合医疗、Medicus Pharma Ltd.涨幅较大，Hims & Hers Health, Inc.、Medicus Pharma Ltd.、Inmed Pharmaceuticals Inc.较为活跃，换手率分别为11.07%、3.17%、2.24%，振幅较大的相关个股有Hims & Hers Health, Inc.、Ironwood医药、Canopy Growth Corporation，振幅分别为2.99%、2.00%、1.87%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213025a6b2aa4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213025a6b2aa4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1699723380.USD","UTHR","LU1571399168.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159454448","title":"美国联合医疗宣布20亿美元股票回购授权并启动15亿美元加速回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1159454448","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159454448?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:04","pubTimestamp":1773054298,"startTime":"0","endTime":"0","summary":"美国联合医疗公司公布了一项高达20亿美元的股票回购授权，并同步启动金额达15亿美元的加速股票回购项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1699723380.USD","LU1571399168.USD","UTHR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102041348","title":"美国联合医疗尚有5亿美元额度可用于未来一年股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1102041348","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102041348?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054176,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，公司目前仍拥有5亿美元的回购授权额度，该额度将在未来一年内用于实施额外的股份回购计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4532","UTHR","BK4139","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616558327","title":"美国联合医疗跌2.89% 股价跌破500美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558327","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616558327?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:39","pubTimestamp":1772548778,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时39分，美国联合医疗股票出现波动，股价快速跳水2.89%。截至发稿，该股报498.96美元/股，成交量1.582万股，换手率0.04%，振幅2.79%。美国联合医疗股票所在的制药行业中，整体跌幅为0.48%。此外，该公司正在开发一系列项目，其中包括用于治疗肺动脉高压和其他病症的现有产品和新产品的新适应症和输送装置。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223939a69e060f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223939a69e060f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","BK4139","BK4532","UTHR","LU1699723380.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116122081","title":"美国联合医疗Ralinepag三期研究达主要终点，临床改善率达47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116122081","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116122081?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:32","pubTimestamp":1772451132,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其肺动脉高压治疗药物Ralinepag的三期临床试验成功达到主要研究终点。数据显示，与安慰剂组相比，Ralinepag治疗组患者实现47%的临床改善率，这一结果标志着该药物在改善患者运动能力和延缓疾病进展方面展现出显著疗效。\n此次突破性进展为肺动脉高压患者提供了新的治疗希望，也进一步巩固了美国联合医疗在罕见病治疗领域的领先地位。研究人员指出，该药物独特的作用机制可能为现有治疗方案提供重要补充。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","BK4139","LU1571399168.USD","LU1699723380.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112670692","title":"美国联合医疗公布ralinepag关键性肺动脉高压研究结果：临床恶化风险降低55%，疗效卓越且具高度统计学意义","url":"https://stock-news.laohu8.com/highlight/detail?id=1112670692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112670692?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:30","pubTimestamp":1772451029,"startTime":"0","endTime":"0","summary":"美国联合医疗公司宣布，其在研药物ralinepag于关键性肺动脉高压研究中取得突破性成果——临床恶化风险显著降低55%。该结果展现出卓越的疗效，并具有高度统计学意义。\n这项研究针对肺动脉高压患者群体展开，数据显示ralinepag治疗组在主要终点指标上表现突出。风险降低幅度远超常规预期，统计显著性达到较高水平，为药物后续审批及临床应用奠定坚实基础。\n肺动脉高压作为进行性重症疾病，临床恶化风险直接影响患者预后。此次研究成果不仅验证了ralinepag的治疗潜力，更为该疾病领域提供了新的治疗方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1571399168.USD","BK4139","LU1699723380.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unither.com","stockEarnings":[{"period":"1week","weight":0.0268},{"period":"1month","weight":-0.0265},{"period":"3month","weight":-0.0973},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.6517},{"period":"ytd","weight":0.0531}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"United Therapeutics Corporation于1996年6月成立于特拉华。它是一家生物科技公司，致力于能解决患有慢性病和有生命危险病人未被满足的医疗需求的独特产品的开发和商业化。它的收入主要来源于曲前列尼尔、Tyvaso和他达拉非的销售。他们的市场和销售人员会努力使他们的产品在他们那些被授权的国家买到。这些主要是由他们在美国的专业经销商和其它的国际经销商做的。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.005391},{"month":2,"riseRate":0.518519,"avgChangeRate":0.021742},{"month":3,"riseRate":0.481481,"avgChangeRate":0.013636},{"month":4,"riseRate":0.407407,"avgChangeRate":-0.022031},{"month":5,"riseRate":0.555556,"avgChangeRate":0.047064},{"month":6,"riseRate":0.518519,"avgChangeRate":0.026827},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040787},{"month":8,"riseRate":0.5,"avgChangeRate":0.049904},{"month":9,"riseRate":0.444444,"avgChangeRate":0.055311},{"month":10,"riseRate":0.62963,"avgChangeRate":-0.003162},{"month":11,"riseRate":0.62963,"avgChangeRate":0.05551},{"month":12,"riseRate":0.592593,"avgChangeRate":0.029941}],"exchange":"NASDAQ","name":"美国联合医疗","nameEN":"United Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国联合医疗,UTHR,美国联合医疗股票,美国联合医疗股票老虎,美国联合医疗股票老虎国际,美国联合医疗行情,美国联合医疗股票行情,美国联合医疗股价,美国联合医疗股市,美国联合医疗股票价格,美国联合医疗股票交易,美国联合医疗股票购买,美国联合医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国联合医疗(UTHR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国联合医疗(UTHR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}